Rapid Nexus Reports the US FDA’s 510(k) Clearance of Hemastyl Gel Device to Support Wound Healing

Shots:

• The US FDA has granted 510(k) clearance to the Hemastyl gel device to support chronic wound healing 
• The Hemastyl gel is a topical formulation that enhances the tissue-repair environment to support wound closure, while the Periwound NerveStim device works with Hemastyl to restore periwound function
• The Periwound NerveStim device is in final FDA approval stages, with Rapid Nexus finalizing its Breakthrough Device Designation submission, expected in 30–45 days to expand use, speed reimbursement, & improve patient access

Ref: PRNewsWire | Image: Rapid Nexus | Press Release

Related News:- Thermo Fisher Scientific’s EXENT System Receives the US FDA’s 510(k) Clearance to Aid Multiple Myeloma Diagnosis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com